Stock News

Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
4 Drug Stocks Getting Smashed
UPDATE 1-Eli Lilly's bio-medicines head to leave next month
Lilly Announces Changes in Senior Leadership
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache

As seen on...